Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$15.45 - $29.52 $305,322 - $583,374
-19,762 Reduced 61.74%
12,247 $244,000
Q1 2022

May 16, 2022

SELL
$21.94 - $42.51 $919,527 - $1.78 Million
-41,911 Reduced 56.7%
32,009 $882,000
Q4 2021

Feb 14, 2022

SELL
$36.09 - $53.79 $249,670 - $372,119
-6,918 Reduced 8.56%
73,920 $3.05 Million
Q3 2021

Nov 15, 2021

SELL
$35.62 - $52.97 $57.9 Million - $86.1 Million
-1,625,802 Reduced 95.26%
80,838 $3.76 Million
Q2 2021

Aug 16, 2021

SELL
$32.94 - $56.62 $22.7 Million - $39.1 Million
-690,141 Reduced 28.79%
1,706,640 $68.2 Million
Q1 2021

May 17, 2021

SELL
$44.47 - $81.38 $25.2 Million - $46.2 Million
-567,454 Reduced 19.14%
2,396,781 $129 Million
Q4 2020

Feb 16, 2021

SELL
$32.49 - $61.88 $3.69 Million - $7.02 Million
-113,465 Reduced 3.69%
2,964,235 $145 Million
Q3 2020

Nov 16, 2020

SELL
$26.73 - $35.67 $2.4 Million - $3.21 Million
-89,879 Reduced 2.84%
3,077,700 $100 Million
Q2 2020

Aug 14, 2020

SELL
$19.49 - $28.11 $7.76 Million - $11.2 Million
-398,097 Reduced 11.16%
3,167,579 $82 Million
Q1 2020

May 15, 2020

SELL
$16.13 - $30.17 $3.33 Million - $6.22 Million
-206,283 Reduced 5.47%
3,565,676 $86.7 Million
Q4 2019

Feb 14, 2020

SELL
$20.78 - $29.99 $1.09 Million - $1.58 Million
-52,667 Reduced 1.38%
3,771,959 $105 Million
Q3 2019

Nov 14, 2019

SELL
$23.87 - $30.93 $1.12 Million - $1.45 Million
-46,825 Reduced 1.21%
3,824,626 $91.8 Million
Q2 2019

Aug 13, 2019

BUY
$22.1 - $28.56 $9.24 Million - $11.9 Million
418,227 Added 12.11%
3,871,451 $110 Million
Q1 2019

May 17, 2019

BUY
$12.0 - $25.76 $41.4 Million - $89 Million
3,453,224 New
3,453,224 $86.4 Million

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.23B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Gilder Gagnon Howe & CO LLC Portfolio

Follow Gilder Gagnon Howe & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.